Sign In
Buy XOMA
$41.70
+0.0100 (+0.0240%)
At Close: Jun 03, 2026
XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements
04:30pm, Monday, 17'th Mar 2025
Doubled the royalty and milestone portfolio to over 120 royalty assets with significant milestone potential through five transactions in 2024
Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences
07:00am, Tuesday, 25'th Feb 2025
Capital will fund Castle Creek's D-Fi Phase 3 clinical trial for patients with dystrophic epidermolysis bullosa through topline data results Ligand invested $50 million and a syndicate of co-investors
XOMA Royalty to Present at Investor Conferences in March
04:05pm, Monday, 24'th Feb 2025
EMERYVILLE, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the fol
XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
07:30am, Tuesday, 04'th Feb 2025
EMERYVILLE, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the Opp
XOMA Royalty Declares Quarterly Preferred Stock Dividends
07:30am, Thursday, 19'th Dec 2024
EMERYVILLE, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA's Se
What Makes XOMA Royalty (XOMA) a New Buy Stock
01:06pm, Monday, 11'th Nov 2024
XOMA Royalty (XOMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
XOMA Royalty (XOMA) Reports Q3 Loss, Tops Revenue Estimates
10:00am, Thursday, 07'th Nov 2024
XOMA Royalty (XOMA) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.60 per share a year ago.
XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
07:30am, Thursday, 07'th Nov 2024
Zevra's MIPLYFFA™ (arimoclomol) received FDA approval and became the sixth commercial asset in XOMA Royalty's portfolio
XOMA Royalty has acquired 50 percent of Twist's existing royalty and milestone economics for $15 million XOMA Royalty's portfolio now holds over 100 assets ranging from revenue-generating commercial t
XOMA Royalty's Preferred Shares: High-Yield Dividends From Biotech Royalties
10:31am, Tuesday, 15'th Oct 2024
XOMA Royalty Corporation offers diversified revenue streams from milestone and royalty rights in various therapeutic areas, providing stable returns with lower clinical trial risks. The company's pref
I Am Banking On The Silver Tsunami With Big Dividends
10:30am, Saturday, 12'th Oct 2024
There are sectors that experience demand irrespective of economic climate. I like cold hard cash placed in my account. We discuss big dividends from healthcare, yields +8.3%.
XOMA Stock Dips Amidst Biotech Sector Decline
03:53pm, Thursday, 03'rd Oct 2024
XOMA (XOMA, Financial), a company engaged in biotechnology royalties, saw its stock price plummet by 5.36%, with the latest price reported at $25.91. The trading volume reached 3,638 shares, represent
XOMA Royalty Declares Quarterly Preferred Stock Dividends
05:30am, Monday, 23'rd Sep 2024
EMERYVILLE, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cas
XOMA Royalty to Present at Upcoming Investor Conferences in September
07:30am, Wednesday, 04'th Sep 2024
EMERYVILLE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the fo
XOMA Royalty (XOMA) Reports Q2 Loss, Tops Revenue Estimates
09:46am, Tuesday, 13'th Aug 2024
XOMA Royalty (XOMA) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.59 per share a year ago.
